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Glucose uptake by adipocytes
Glucose tolerance
Insulin signaling pathwayThe bis(1,2-dimethyl-3-hydroxy-4-pyridinonato)oxidovanadium(IV), VO(dmpp)2, has shown anti-diabetic
effects by in vitro studies in Wistar (W) rat adipocytes and in vivo in obese Zucker rats. The aim of this work is
to confirm the therapeutic properties of VO(dmpp)2 in non-obese type 2 diabetic Goto-Kakizaki (GK) rats. An
in vivo study was carried out, treating W and GK rats during 21 days with a daily dose of VO(dmpp)2
(44 μmol/kg). It was shown that VO(dmpp)2 doesn't affect the normal increase of body weight of both W and
GK rats, after 8 days of treatment ameliorates glycemia in GK rats (8.4 ± 0.3 vs 10.1 ± 0.2 mM in GK control,
P b 0.001) but doesn't interfere with glucose levels in W rats and, after 21 days of treatment, improves the
glucose intolerant profile of GK rats (13.1 ± 0.5 vs 20.6 ± 0.7 mM/min in GK control, P b 0.001), despite no in-
crease of plasma insulin levels during glucose tolerance test. Additionally, it was demonstrated that VO(dmpp)2
significantly enhances [3-3H]-glucose uptake by W and GK rat adipocytes (non-toxic concentration of 100 μM:
respectively 193 ± 20 and 254 ± 21%, P b 0.001, relative to the basal value) showing an efficacy similar to insu-
lin 1.72 nMand better than the same concentration of BMOV (P b 0.01).Western blotting revealed that inWand
GK rats VO(dmpp)2 significantly promotes IRS2 (P b 0.05) and p-AKT expression (P b 0.001 and P b 0.05,
respectively, relative to the respective controls) and in GK animals reduces the increase of PTP1β expression
(P b 0.001, relative to GK control).
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Type 2 diabetes (T2D) is characterized by hyperglycemia due to a
combination of reduced insulin sensitivity in liver and extra hepatic tis-
sues such as muscle and fat cells and impaired insulin secretion by the
pancreatic β-cells [1–5]. Several oral anti-diabetic drugs are available,
but suffer from long-term inadequate efficacy and a number of adverse
effects [6,7]. Therefore, T2D still remains amajor health concern all over
the world, and it is of utmost importance to find new therapeutic
approaches to treat diabetes. Intensive research has been carried out
to synthesize new, more efficient and less toxic drugs and understand
their mechanism of action to ameliorate diabetic features.
In the last two decades vanadium compounds (VCs) have attracted
much interest due to their demonstrated pharmacological properolecular Medicine and Surgery,
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ghts reserved.ties [8,9]. In particular, their potential insulin mimetic capacity has been
extensively investigated [10–16]. It has been shown that VCs can be
used to mitigate insufficient insulin response in DM thus presenting
insulin-mimetic properties in vitro and [17–20] in vivo [21–24], and two
of them were tested in clinical trials [25]. To date, the main limitation
for the clinical use of VCs in the treatment of diabetes has been their
potential toxicity [26]. Most recently, renal changes detected in a three-
month preclinical safety program required discontinuation of a VC devel-
opment program that had already proceeded to early Phase IIa clinical
testing [http://www.medicalnewstoday.com/releases/136363.php].
However, studies in this area continue to be pursued in an attempt to
minimize the likelihood of toxic effects [27].
A large number of vanadium (IV and V) complexes have been synthe-
sized, structurally characterized [28–31] and their biological activity test-
ed using adequate cellular models by measuring glucose uptake levels
[32,33], inhibition of free fatty acid release [33,34] and in vivo studies
with diabetic rat models to test their capacity to reverse diabetic features
[23,24,35,36]. Among the many vanadium compounds reported in the
literature, emphasis is given to the bis(matolato)oxidovanadium(IV)
(BMOV) [11,14,37] and the similar one bis(ethylmaltolato) oxido-
vanadium(IV) (BEOV) [25], the only vanadium compounds tested in
clinical trials to date, but other compounds like bis(1,2-dimethyl-
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[31,33,36–41], bis(picolinato)oxidovanadium(IV) [VO(pic)2] [24,42,43]
and bis(allixinato)oxidovanadium(IV) [18,44,45] have also attracted
much interest due to the positive results which have been obtained
through in vitro and in vivo studies.
In an attempt to interpret the insulinmimetic activity of VCs, in par-
ticular to investigate how they interfere in the insulin pathway and in
glucose and lipid metabolism, studies have been carried out to findmo-
lecular targets for these compounds [16,29,46–48]. Nevertheless, the
exact cellularmechanism of action of VCs appears to involve a combina-
tion of several post-receptor events in the insulin-signaling cascade. It
has been demonstrated that protein tyrosine phosphatases (PTPases)
play a complex role in the regulation of glucose-induced insulin secre-
tion and increased expression and/or activity of a specific PTPase may
contribute to impaired insulin sensitivity in several biological systems
[49–51]. Vanadium salts and VCs have been shown to inhibit these
enzymes [49,50,52], particularly some VCs inhibit phosphotyrosine
phosphatase 1β (PTP1β) [50,52] within the insulin signaling cascade
thus maintaining this enzyme in the phosphorylated state [27]. The
mechanism of the insulin-mimetic action of VCs has been investigated
in detail and some results have ruled out stimulation of phosphotyrosine
kinases, important proteins of the insulin cascade [50,53–55]. Stimulation
of glucose uptake via GLUT4 transporter has also been demonstrated for
BMOV [56].
The VO(dmpp)2 compound has been extensively studied for a
structural characterization [30,31] and to investigate its therapeutic
properties using adequate cellular models [33,37–40]. Recently, it
was shown that it is able to restore normal glucose and lipid metab-
olism in an obese pre-diabetic animal model, the Zucker fatty rats
[36]. These results demonstrated promising anti-diabetic and anti-
obesity activity of this vanadium compound which was shown to
be more effective than BMOV [33]. The aim of the present work is
to study the therapeutic properties of this vanadium compound in
an animal model of T2D, the Goto-Kakizaki (GK) rats, to validate
previous data and to provide some insights into the potential molec-
ular mechanisms of its anti-diabetic action. The GK rat is a non-
obese substrain of Wistar (W) rat origin, developing T2D early in
life. Glucose intolerance is most likely primarily due to impaired
β-cell function in the background of a polygenic inheritance. In ad-
dition, secondary to chronic hyperglycemia impaired insulin action
may superimpose [57,58]. Adipocytes isolated from GK rats were
used to characterize the effects of VO(dmpp)2 on glucose cell up-
take. The obtained results were compared with those with BMOV,
using W rat adipocytes as a control. In addition, a chronic treatment
of GK rats with VO(dmpp)2 during 21 days was carried out to investi-
gate the effects on glycemia, plasma insulin levels and glucose tolerance.
Furthermore, Western blotting was used to clarify the mechanism of
action at the molecular level, looking for VO(dmpp)2 targets in the
insulin signaling pathway.2. Materials and methods
2.1. Animals
Male type 2 diabetic GK rats were bred at the Department of
Molecular Medicine and Surgery (Karolinska Institutet, Stockholm,
Sweden). Normal male W rats were purchased from a commercial
breeder (Charles Rivers, Sulzfed, Germany) and used as non-diabetic
controls. All animals were kept at 22 °C on 12/12-hour light/dark
cycle with food and water available ad libitum. For the in vitro study,
10–12-week-old rats were used and for the in vivo study, the treatment
was initiated in 6-week-old rats.
The present investigation was performed in accordance with the
guiding principles in the care and use of animals (Laboratory Animal
Ethics Committee of the Karolinska Institutet, N499/11).2.2. Glucose uptake studies
The experiments were performed with adipocytes isolated from
rat epididymal fat, digested during 120 min at 37 °C with 0.25 mg/mL
of type II collagenase (Sigma-Aldrich) in a Krebs-Ringer medium
(139 mM NaCl, 5.4 mM KCl, 1 mM NaH2PO4, 1 mM MgSO4, 2.2 mM
CaCl2, pH 7.4) buffered with 20 mM Hepes, containing 2% BSA (bovine
serum albumin) with 7 mMglucose. Isolated cells were obtained by fil-
tration through a coarse nylon mesh (250 μm) before being washed
twice with a 2% BSA buffer. After isolation, 1% adipocyte suspension
was incubated for 2 h at 37 °C with [3-3H]-glucose (1 μCi/mL, Perkin
Elmer), 1 mM D-glucose solution (Sigma Aldrich) and VO(dmpp)2 or
BMOV in a range of concentrations from 10 μM to 750 μM. After the
incubation, the vials containing the cell suspensions were transferred
into ice to stop the reactions and 3 mL of scintillation cocktail (2 M
PPO (2,5-diphenyloxazole) and 0.02 M POPOP (1,4-Bis(4-methyl-5-
phenyl-2-oxazolylbenzene))), dissolved in toluene, Sigma Aldrich)
was added to each vial at room temperature. The glucose uptake
was determined by measuring the radioactivity of 3H-glucose incor-
porated in the de novo synthesized lipids, which is proportional to
3H-glucose taken up by the cells, with the Liquid Scintillator Analyz-
er (Tri-Carb 1900TR, Packard) [60]. The same experiment was car-
ried out with insulin concentrations ranging from 0.1 to 172 nM
used as control of glucose uptake, as well as with 1.72 nM of insulin
and 25 μM or 250 μMVO(dmpp)2, to check the insulin enhancement
effect of VO(dmpp)2.
2.3. In vivo VO(dmpp)2 treatment
The compound bis(1,2-dimethyl-3-hydroxy-4-pyridinonato)
oxovanadium(IV), VO(dmpp)2, was synthesized according to a pub-
lished procedure [31]. Its purity and structure was confirmed by ele-
mental analysis and spectroscopic data. A 3 mM VO(dmpp)2 saline
solution (0.9% NaCl) at pH 7.4 was prepared. This solution was fil-
tered through a 0.2 μm membrane and stored at 4 °C. In the chronic
treatment, both GK and W rats were treated during 21 days with
VO(dmpp)2 by a once daily intraperitoneal (i.p.) injection at a dose
of 44 μmol/kg body weight [18]. For the acute treatment a single
VO(dmpp)2 dose of 44 μmol/kg was administered to each animal
30 min before the experiment. A saline solution (0.9%NaCl)was injected
as placebo in both GK and W rats to be used as control.
2.4. Glycemia and body weight
Blood samples for determination of glucose were taken after small
tail incisions. Blood glucose levels weremonitored by the glucose de-
hydrogenase method (Accu-Check Aviva, Roche Diagnostics) [61]
every 2 days before injection of VO(dmpp)2 or placebo. During the
experimental period, the body weight of all animals was measured
daily.
2.5. OGTT (oral glucose tolerance test)
After 21 days of chronic treatment (at day 21), as well as 30 min
after the acute treatment, OGTTs were performed in overnight fasted
rats. Tail vein blood samples were collected at 0, 15, 30, 60, 90, 120
and 150 min after an oral gavage of glucose (3 mg/g body weight,
D-glucose, Sigma-Aldrich) and blood glucose levels were immediately
measured by the glucose dehydrogenase method [61]. In addition,
blood samples collected at 0, 30 and 120 min after the glucose load
were placed into ice-cold heparinized tubes, plasma was immediately
separated by centrifugation (8000 ×g, 10 min, 4 °C) and plasma insulin
was quantified using a radioimmunoassay [62]. Glucose homeostasis
was assessed by calculating the area under the curve (AUC) of plasma
glucose levels.
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Proteins were extracted from 300 mg of frozen adipose tissue col-
lected from the animals under study, using a RIPA lysis buffer containing
1 mg/ml phenylmethylsulfonyl fluoride (PMSF), 1 mM Na3VO4, 1 mM
NaF (Sigma-Aldrich), 1× protease inhibitors cocktail (Roche Diag-
nostics), 1× phosphatase inhibitor cocktail (Roche Diagnostics).
Adipose tissue lyses were performed in a homogenizer tissue
(PT-2000, Polytron, Kinematica AG). Denaturizing samples were
separated on SDS-PAGE and blotted onto nitrocellulose membranes
(Sigma-Aldrich). After blocking with 5% fat-free milk, membranes
were probed for IRS-2, AKT2, phospho-Thr308-AKT, PTP1B and
GAPDH protein detection using appropriate antibodies: anti-IRS-2
(sc-8299, Santa Cruz), anti-AKT-2 (3063, Cell Signaling), anti-phospho-
Thr308-AKT (4056, Cell Signaling), anti-PTP1B (sc-1718, Santa Cruz)
and anti-GAPDH (3683, Cell Signaling). Appropriate horseradish peroxi-
dase (HRP)-conjugated secondary antibody was used for detection:
HRP-conjugated anti-rabbit (7074, Cell Signaling). Proteins were
visualized using an enhanced chemiluminescence procedure (34080,
SuperSignal West Pito Cheluminescent Substrate, Thermo Scientific)
or (p90720, Immoblion Western, Chemulinescent HRP substrate,
Millipore). Quantification was carried out using Luminescent Image
Analyzer (Image Reader LAS-100 Pro v1.0, Fujifilm) and ImageJ
software (v1.47b, National Institute of Health).
2.7. Statistical analysis
Data are expressed as means ± SEM. Student's paired t-test was
used to evaluate the significance of changes of glucose uptake within a
group. Two-way analysis of variance was followed by the Student–
Bonferroni multiple-range test to estimate the significance of differ-
ences between groups for the body weight, glycemia during treatmentFig. 1. Glucose uptake induced by insulin, VO(dmpp)2 and BMOV onWistar and GK adipocyte
(○, n = 9) and GK (■, n = 11) rats for (a) insulin (b) VO(dmpp)2 and (c) BMOV stimulation
GK (n = 11) adipocytes induced by different concentrations of insulin, VO(dmpp)2 and BMOV
basal value; §P b 0.05, §§P b 0.01, §§§P b 0.001 vs respective 1.72 nM of insulin; †P b 0.05, ††P b
concentration of VO(dmpp)2.and OGTT. One-way analysis of variance was followed by the Student–
Bonferroni multiple-range test to estimate the significance of differ-
ences between groups for area under curve (AUC) of blood glucose
levels during OGTT. One-way analysis of variance was followed by the
Student–Newman–Keuls multiple-range test to estimate the signifi-
cance of differences between groups for Western Blot analysis. A value
of P b 0.05 was considered as statistically significant. Data were ana-
lyzed using GraphPad Prism (v5.0, GraphPad Software).
3. Results and discussion
The anti-diabetic properties of VO(dmpp)2 were evaluated by
in vitro studies with primary GK rat adipocytes and in vivo studies in
GK rats. The effect of this compound on some abnormal parameters in-
dicative of diabetes was tested. Its capacity to improve glucose uptake
by adipocytes was measured. Body weight and blood glucose levels of
GK rats subjected to a daily administration of this compound during
21 days were periodically determined and at the end of the chronic
treatment (day 21), an OGTT was also carried out as well as 30 min
after the acute treatment.
3.1. In vitro studies with VO(dmpp)2 in isolated rat adipocytes
The GK rats used in this study had significantly lower body weight
than the W rats (286 ± 15 vs 336 ± 11 g, P b 0.001), in agreement
with published data which reported that although an increase in the
number of adipocytes occurs before weaning, decreased body weight
and leanmass are observed in the GK rats [63] and displayed hypergly-
cemia (7.0 ± 0.2 vs 5.1 ± 0.2 mM, P b 0.001). Moreover glucose
uptake was significantly impaired in adipocytes from GK rats when
compared with W rats (81 ± 4 vs 121 ± 7 DPM/h, P b 0.001, DPM =
disintegration per minute). The improvement of glucose uptake bys. (A) Dose response curves of glucose uptake (in DPM/h, disintegration per min/h) on W
. (B–C) Percentage of glucose uptake (relative to basal value of 100%) by W (n = 9) and
. Data are shown as mean values ± SEM. *P b 0.05, **P b 0.01, ***P b 0.001 vs respective
0.01, †††P b 0.001 vs respective 17.2 nM of insulin; ##P b 0.01, ###P b 0.001 vs the same
Fig. 2. Body weight (A) and blood glucose levels (B) of Wistar and GK rats submitted to
placebo or VO(dmpp)2 treatment for 21 days. A) Values of rat body weight (g) assessed
everyday during 21 days of treatment in W rats with placebo (□) and VO(dmpp)2 (■)
and in GK rats with placebo (△) and VO(dmpp)2 (▲); B) Blood glucose levels (mM)mea-
sured every 2 days during placebo (□) and VO(dmpp)2 treatment (■) inW rats; placebo
(△) and VO(dmpp)2 treatment (▲) in GK rats. Data are shown as mean values ± SEM
(n = 8). ###P b 0.001 vs GK rats; *P b 0.05, **P b 0.01, ***P b 0.001 vs GK rats treated
with placebo.
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confirm the therapeutic properties of VO(dmpp)2 previously demon-
strated in in vitro studies with W rat adipocytes [33], further experi-
ments with GK rat adipocytes were performed to assess the capacity
of this VC to promote glucose uptake. Parallel studies with the promis-
ing compound BMOV [14,33], as well as with VO(dmpp)2 in the pres-
ence of insulin [33], were also carried out, with insulin as a control.
To establish the adequate concentrations of insulin, VO(dmpp)2 and
BMOV to be used in these studies, a dose response assaywas carried out
with different concentrations of these candidate drugs (Fig. 1A). GK rats,
due to their characteristic insulin resistance, present a significantly
lower response (P b 0.05) than Wistar rats to glucose uptake when
stimulated with increasing insulin concentrations (Fig. 1A). W and GK
adipocytes also respond to increasing concentrations of VO(dmpp)2
and BMOV, although a better response is obtainedwith the former com-
pound (Fig. 1A). Moreover, these data indicate that both vanadium
compounds decrease the differences in glucose uptake capacity be-
tween the diabetic and healthy rats.
Fig. 1B–C shows the normalized values of glucose uptake percentage
for W and GK adipocytes, in the presence of different concentrations of
insulin and non-toxic concentrations of the VC [33], compared with the
respective baselines (considered as 100%). The results showed that
100 μM VO(dmpp)2 and 500 μM BMOV had effects on glucose uptake
similar to those of 1.72 nM insulin, in adipocytes from both W and GK
rats. The in vivo physiological concentration of insulin is approximately
1.72 nM and the highest response is achieved with 17.2 nM of insulin
[33]. When adipocytes of W rats (Fig. 1B) were incubated with
VO(dmpp)2, glucose uptake was enhanced 1.9 (100 μM: 193 ± 20%,
P b 0.01) to 3.2 times (500 μM: 322 ± 16%, P b 0.001) compared to
baseline (100 ± 9%), while glucose uptake induced by BMOV was
only 1.1 times (100 μM: 111 ± 20%, not significant) to 1.5 times higher
(500 μM: 153 ± 23%, P b 0.05) than baseline. Thus, the effects of BMOV
were significantly lower than those of VO(dmpp)2 (100 μM P b 0.01;
250 and 500 μM P b 0.001). Similarly, VO(dmpp)2 improved glucose
uptake in adipocytes of GK rats (Fig. 1C) 2.5 (100 μM: 254 ± 21%,
P b 0.001) to 4.2 times (500 μM: 424 ± 37%, P b 0.001), while in
the same concentrations, the BMOV improved only 1.5 (100 μM:
145 ± 26%, P b 0.05) to 2.2 times (500 μM: 219 ± 37%, P b 0.01) the
basal glucose uptake (100 ± 8%). These findings demonstrate and con-
firm previously published results [33] that VO(dmpp)2 is more effective
than BMOV, concerning induced glucose uptake levels, showing a
behavior similar to that of insulin. Since insulin signaling is impaired
in T2DM it is of great interest to find compounds acting through mech-
anisms that regulate glucose uptake in peripheral tissues.
Studies of glucose uptake in the presence of VO(dmpp)2 and insulin
were also carried out (data not shown), to check if the effects of
VO(dmpp)2 and insulin are additive in GK rat adipocytes. Glucose
uptake in the presence of 25 μM or 250 μM of VO(dmpp)2, and in
the absence or presence of 1.72 nM insulin, did not show significant
difference. These results indicate that VO(dmpp)2 does not behave as an
insulin enhancer, in agreement with previously published data [33].
3.2. Effect of VO(dmpp)2 treatment on body weight, blood glucose levels
and glucose tolerance profile
The in vivo experiments have assessed the effects of VO(dmpp)2 on
diabetic (GK) and non-diabetic (W) animals. Each group of animals
had its own control group submitted to a placebo treatment At day
0, GK rats had a significantly lower body weight than W animals
(respectively, 148 ± 4 vs 200 ± 6 g, P b 0.001) (Fig. 2A). After 21 days
of treatment the body weight was 353 ± 4 and 233 ± 5 g for control
Wistar and GK rats; 342 ± 6 and 225 ± 3 g for VO(dmpp)2 treated
Wistar and GK, respectively. Thus, a similar body weight gain was ob-
served for placebo and VO(dmpp)2 treated animals of each type,
which indicates that VO(dmpp)2 had no effect on the normal weight
development of GK and W rats. VO(dmpp)2 was shown to induce adecreased body weight gain in obese Zucker rats [36], in contrast with
the lack of effect on the body weight of non-obese GK rats.
Chronic hyperglycemia was demonstrated in GK rats compared
with non-diabetic W rats (Fig. 2B) throughout the whole treatment
period. At day 0, blood glucose concentration of GK rats was significant-
ly higher (10.0 ± 0.3 mM, P b 0.001) when compared with W rats
(7.9 ± 0.3 mM), in agreement with the hyperglycemic state of T2D.
There were no significant differences in blood glucose levels between
placebo and VO(dmpp)2 treated W rats throughout the study
(6.8 ± 0.2 and6.6 ± 0.2 mM, respectively, at day 21) (Fig. 2B). Howev-
er, from the 8th day, a significant decreasewas observed for VO(dmpp)2
treated relative to placebo treatedGK rats (8.4 ± 0.3 vs10.1 ± 0.2 mM,
P b 0.001), which was maintained until the last day of treatment
(8.3 ± 0.1 vs 9.4 ± 0.2 mmol/l, P b 0.05). The values obtained for
VO(dmpp)2 treated Wistar and GK rats are statistically different
(P b 0.001), but there is a significant difference between VO(dmpp)2
treated and non-treated GK animals from 8th to 21th day. Therefore,
this chronic treatment with VO(dmpp)2 reduced hyperglycemia in the
diabetic animals, possibly by improving glucose uptake in adipocytes
and other tissues.
The effect of VO(dmpp)2 on the glucose homeostasis of W and GK
rats was also investigated through an OGTT, which is currently used to
assess clinical pre-diabetic anddiabetic conditions [64,65]. TheOGTT as-
sesses glucose tolerance of the animal by measuring blood glucose
levels for a period of time after the administration of a glucose load. In
insulin sensitive animals, blood glucose concentration will drop after a
certain period of time, restoring the normal glucose values. However,
in conditions of impaired glucose metabolism, insulin resistance or
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concentration remains high for a longer period of time [66–68]. The
OGTT results demonstrated that glucosewas significantly better tolerat-
ed in W than in GK rats (Fig. 3A, P b 0.001) and that the 21-day treat-
ment with VO(dmpp)2 improved significantly glucose tolerance in GK
rats (Fig. 3A, P b 0.05 or less; values of area under curve 20.6 ± 0.7 vs
13.1 ± 0.5 mM/min in placebo andVO(dmpp)2 treatedGK rats, respec-
tively, P b 0.001, Fig. 3B). Interestingly, this glucose-lowering effect by
VO(dmpp)2 was not seen in the W rats (8.7 ± 0.2 mM/min in placebo
treated W rats and 8.0 ± 0.4 mM/min in VO(dmpp)2 treated W rats)
(Fig. 3B), indicating that the compounddoes not appear to induce hypo-
glycemia in non-diabetic rats, but may interact specifically with patho-
logical mechanisms in diabetes.
To further assess the effects of VO(dmpp)2 on glucose homeostasis,
plasma insulin levels in OGTT were evaluated, before glucose load
(0 min), at the maximum effect of the overload (30 min) and 120 min
after glucose load, to test the ability of the animal to respond to a
rapid glucose challenge (Fig. 3C–D). In W rats, in which VO(dmpp)2
treatment did not affect glucose tolerance (Fig. 3A–B), plasma insulin
levels were significantly lower than in animals treated with placebo
throughout the test (respectively, at 0 min: 7.1 ± 1.8 vs 20.7 ±
3.1 μU/mL, P b 0.01; at 30 min: 29.8 ± 3.8 vs 50.9 ± 3.7 μU/mL,
P b 0.05; at 120 min: 7.6 ± 1.0 vs 21.2 ± 5.5 μU/mL, P b 0.05)
(Fig. 3C). This discrepancy can be explained by the increased glucose
uptake induced by VO(dmpp)2. However, the kinetics of plasma insulin
during theOGTT remained the same. After 30 min, plasma insulin levels
in W rats treated with placebo or VO(dmpp)2 were significantly higher
than their respective groups before the glucose challenge (20.7 ± 3.1 vs
50.9 ± 3.7 μU/mL, P b 0.01; 7.1 ± 1.8 vs 29.8 ± 3.8 μU/mL, P b 0.001,
respectively) (Fig. 3C). Plasma insulin concentrations decreased after
120 min compared to 30 min (50.9 ± 3.7 vs 21.2 ± 5.5 μU/mL,
P b 0.01; 29.8 ± 3.8 vs 7.6 ± 1.0 μU/mL, P b 0.001, respectively) butFig. 3.Glucose tolerance profile (A–B) and plasma insulin levels (C–D) after 21 days of treatmen
or VO(dmpp)2. A) Blood glucose values (mM) during anOGTT after 21 days of treatment inW r
(▲); B) Values of area under curve (AUC), expressed as mM/min, obtained from the curves of
placebo or VO(dmpp)2, shown in Fig. 3A; C) Plasma insulin levels during an OGTT inW rats treat
with placebo or VO(dmpp)2; E) Blood glucose values (mM) during an OGTT for the control (△,
istered 30 min before the glucose load, n = 7) effects of VO(dmpp)2 inGK rats. Data are shown
vs GK rats treated with VO(dmpp)2; #P b 0.05, ##P b 0.01, ###P b 0.001 vsW rats (Panel A); *
***P b 0.001 vs 0 min of the respective group; ##P b 0.01, ###P b 0.001 vs 30 min of the respe
and ***P b 0.001 vs GK control; $P b 0.05 and $$P b 0.01 vs GK rats under an acute treatment (were not significantly different from basal plasma insulin levels. Indeed,
although blood glucose profiles during OGTT were similar in W rats
treated with VO(dmpp)2 or placebo, plasma insulin levels were lower
in the former than in the latter group of animals. These results suggest
an improvement in glucose uptake which could be by changing signal-
ing pathway of insulin at the storage tissue.
In GK rats, VO(dmpp)2 did not significantly decrease plasma insulin
levels either at basal conditions and after 30 min of the glucose load
(Fig. 3D), compared with GK rats treated with placebo. A significant
decrease in plasma insulin levels was found only at 120 min (Fig. 3D,
45.0 ± 5.1 vs 26.9 ± 4.2 μU/mL, P b 0.05), suggesting an improvement
in glucose tolerance observed during the OGTT (Fig. 3A). As for W rats,
the glucose overload induced, 30 min later, a significant increase in
plasma insulin levels (Fig. 3D) in placebo treated (37.8 ± 4.1 vs
53.5 ± 5.9 μU/mL, P b 0.05) and VO(dmpp)2 treated (25.5 ± 3.8 vs
49.2 ± 2.4 μU/mL, P b 0.001) GK rats (Fig. 3D). After 120 min of the
glucose load, plasma insulin levels were not statistically different from
the basal ones at 0 min, but the group treated with VO(dmpp)2
showed a significant decreasewhen compared to 30 min. Important-
ly, VO(dmpp)2 treated GK rats have shown plasma insulin levels
similar to placebo treated W rats, demonstrating the efficiency of
VO(dmpp)2 to improve the glucose tolerance with less insulin-
resistance in diabetic GK rats [58,59]. These results show that GK
rats treated with VO(dmpp)2 recover from a glucose load with a pro-
file similar to W rats, presenting blood glucose values significantly
lower than those from GK control. This provides clear evidence that
VO(dmpp)2 ameliorates the glucose intolerant profile characteristic
of GK rats and this effect occurs without any significant change in
plasma insulin concentrations at 30 min of OGTT [69,70].
To evaluate the acute affects of VO(dmpp)2 treatment in GK rats, an
OGTTwas carried out in animals whichwere submitted to a single dose
of 44 μmol/kg (animal body weight) of VO(dmpp)2 administeredt and glucose tolerance profile after an acute treatment (E) ofW and GK rats with placebo
atswith placebo (□) and VO(dmpp)2 (■) and inGK ratswith placebo (△) and VO(dmpp)2
blood glucose concentration vs time after the glucose load in W and GK rats treated with
edwith placebo or VO(dmpp)2; D) Plasma insulin levels during anOGTT inGK rats treated
control, n = 8), chronic (21 days,▲, n = 8) and acute (single dose of 44 μmol/kg admin-
asmean values ± SEM (n = 8). ***P b 0.001 vsWrats; §P b 0.05, §§P b 0.01, §§§P b 0.001
**P b 0.001 vsW rats; ###P b 0.001 vs respective control (Panel B); *P b 0.05, **P b 0.01,
ctive group; §P b 0.05, §§P b 0.01 vs respective control (Panel C–D); * P b 0.05, **P b 0.01
Panel E).
120 N. Domingues et al. / Journal of Inorganic Biochemistry 131 (2014) 115–12230 min before the glucose load and the results were compared with GK
rats control and those under a chronic treatment. The obtained data are
shown in Fig. 3E and demonstrate that a chronic treatment with
VO(dmpp)2, is more efficient than an acute one concerning recovery
from a glucose load. The values of blood glucose levels in GK rats control
are statistically different from those submitted to a VO(dmpp)2 treat-
ment (P b 0.001) and there is a significant difference between GK
rats under an acute and chronic treatment (P b 0.001 at 60 min and
P b 0.05 between 60 and 120 min after glucose load) although, at
150 min, these values are similar. Several hypothesis can be formulated
to explain this finding: the improvement of pancreas function and con-
sequently an increase in blood insulin concentration, as a response to a
feeding state, after a long term treatmentwith VO(dmpp)2; the increase
of glucose uptake and regulation of glucose metabolism in adipocytes,
muscle and others peripheral tissues, due to an effect on gene expres-
sion of key proteins involved in glucose homeostasis.
3.3. Effect of VO(dmpp)2 treatment on insulin signaling pathway of
adipose tissue
The decrease in plasma insulin levels at 120 min in GK rats treated
with VO(dmpp)2 suggests a more efficient and faster glucose uptake
than in GK animals treated with placebo. During hyperglycemia, the
body regulates glucose homeostasis by increasing insulin secretion
to improve glucose storage in the target tissues. In T2D, however,
insulin-sensitive cells may be resistant to insulin. As shown in this
study, GK rats have impaired glucose tolerance associatedwith the inef-
fectiveness of insulin stimulated pathway and, thus, decreased glucose
internalization [18]. The treatment with VO(dmpp)2 did not increaseFig. 4.Effects of VO(dmpp)2 treatment on the insulin signalingpathway in adipose tissue ofWa
AKT-2 (C) and p-AKT (D) protein expression in adipose tissue fromWandGK rats treatedwith p
(n = 8). *P b 0.05 vsW rats treated with placebo; §§P b 0.01, §§§P b 0.001 vsW rats treated wplasma insulin levels in GK rats in parallel with improvement of glucose
tolerance. In VO(dmpp)2 treatedW rats a normal glucose tolerance pro-
file was observed despite the significant decrease in plasma insulin
levels, suggesting that VO(dmpp)2 improved glucose uptake at the insu-
lin signaling pathway level.
One of themost importantmetabolic actions of insulin is to promote
glucose uptake into adipocytes, skeletal muscle and others peripheral
tissue. This is accomplished via activation of the PI3K/AKT signaling
pathway and subsequent translocation of GLUT4 from intracellular stor-
age vesicles to the plasma membrane [46,47,53,56,71–73]. Western
blotting was used to assess the effect of VO(dmpp)2 on the insulin sig-
naling cascade in adipocytes, more specifically on four target proteins
involved in glucose uptake. This will allow the identification of key
points of this cascade which are deregulated in insulin resistant cells
[71] and may be affected by VO(dmpp)2.
Insulin receptor substrate 2 (IRS2) is a protein directly involved
in insulin cell stimulation, the first event beyond insulin receptor
activation by tyrosine kinase that unleashes the transmission of intra-
cellular insulin signals [73,74]. Chronic treatment of W and GK rats
with VO(dmpp)2 increased significantly the IRS2 expression compared
with their respective controls treated with placebo (0.72 ± 0.07 vs
0.51 ± 0.04, for W rats; P b 0.05 and 0.66 ± 0.05 vs 0.43 ± 0.03, in
GK rats, P b 0.05) (Fig. 4A). Therefore, the increased IRS2 protein
expression can explain the decrease of chronic hyperglycemia and im-
provement of glucose tolerance. At first glance, these results suggest a
higher sensitivity of the insulin receptor resulting in increased protein
expression in adipose tissue. The protein tyrosine phosphatase PTP1β
inhibits the insulin receptor, preventing the activation of the insulin
signaling pathway. Moreover, PTP1β is known to be overexpressed inndGK rats. Representative immunoblots and densitometry analysis of IRS-2 (A), PTP1β (B),
lacebo or VO(dmpp)2. Data fromdensitometry analysis are shown asmean values ± SEM
ith VO(dmpp)2; #P b 0.05, ###P b 0.001 vs respective control.
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compounds, including BMOV [52]. In GK rats treated with placebo, the
level of PTP1β expression was significantly higher compared to W rats
treated with placebo (0.62 ± 0.03 vs 0.47 ± 0.05, P b 0.05) (Fig. 4B),
characteristics shared with other rodent models of insulin resistance
[74–77]. However, in the GK rats treated with VO(dmpp)2, the PTP1β
expression decreased significantly compared to GK rats treated
with placebo (0.34 ± 0.06 vs 0.62 ± 0.03, P b 0.001) andW rats treat-
ed with VO(dmpp)2 (0.47 ± 0.05, P b 0.01) (Fig. 4B). Therefore, the
VO(dmpp)2 like other vanadium compounds [33,76] inhibited the
PTP1β expression, thereby removing the inhibition of the insulin recep-
tor and promoting the activation of the insulin signaling pathway. Thus
the reduction of PTP1β expression may have contributed to improved
insulin sensitivity in GK rats treated with VO(dmpp)2. The ability of
VO(dmpp)2 to inhibit PTPase activity may be one of the mechanisms
by which it exerts its insulino-mimetic action [75].
Another target of VO(dmpp)2 can be the AKT activity [33]. To
address the role of the AKT pathway in relation to alternate pathways,
it is essential to show that activation of AKT alone is sufficient to
mimic the effects of insulin [78] associated with VO(dmpp)2. In this
study, the modifications in the protein expression involved in the insu-
lin signaling pathway did not affect the expression of AKT2. Indeed, the
levels of AKT2 expression did not change after the in vivo VO(dmpp)2
treatment and were not significantly different between W and GK rats
(Fig. 4C). The phosphorylated-AKT2 (p-AKT) has been implicated in
insulin-regulated glucose uptake into fat cells by promoting the translo-
cation of GLUT4 to the cell surface [56,78]. For this purpose, a Western
blot analysis of the phosphorylated protein was assessed. A significant
increase in the p-AKT expression was observed in W and GK rats
treated with VO(dmpp)2 when compared to their respective controls
treated with placebo (2.54 ± 0.16 vs 1.55 ± 0.08, P b 0.001 in W rats;
1.81 ± 0.14 vs 1.40 ± 0.07, P b 0.05 in GK rats) (Fig. 4D). However,
the expression levels of this protein were significantly lower in GK
rats treated with placebo (1.40 ± 0.07, P b 0.001) or VO(dmpp)2
(1.81 ± 0.14, P b 0.001) compared to W rats treated with VO(dmpp)2
(2.54 ± 0.16) (Fig. 4D).
According to these data, VO(dmpp)2 treatment in GK rats improved
glucose tolerance and decreased the chronic hyperglycemia after 8 days
of treatment. These effects may be explained by the increase of the IRS2
expression, thus improving the insulin sensitivity in adipocytes, by the
inhibition of the PTP1β expression which exerts an inhibitory action
on IRS2 and by the increase of p-AKT expression thus promoting glucose
uptake by GLUT4 [71,72,78].
4. Conclusions
This work clearly demonstrates the in vitro and in vivo insulin mi-
metic effects of VO(dmpp)2 in the GK rats, a T2D animal model. It is
shown by the in vitro study that VO(dmpp)2 improves glucose uptake
in adipocytes, more effectively than BMOV. A chronic in vivo treatment
with VO(dmpp)2 decreases hyperglycemia and improves glucose toler-
ance significantly, although a complete normalization during OGTTwas
not observed inGK rats.Moreover, there is a normal gain of bodyweight
of both diabetic and control VO(dmpp)2 treated rats, and this
compound does not induce hypoglycemia in non-diabetic W rats. In
addition, a better behavior is observed in GK rats submitted to a chronic
treatment than an acute one. All these effects can be explained by the
direct action of VO(dmpp)2 on key proteins of the insulin signaling
cascade, by specifically increasing IRS2 expression and AKT phosphory-
lation and inhibiting PTP1β expression. The combined results here pre-
sented demonstrate the beneficial effects of VO(dmpp)2 in GK rats,
corroborating previously published data and showing the insulin
mimetic activity of this compound. Thus, taking into account the prob-
lems of toxicity associated with vanadium compounds, which should
be minimized, VO(dmpp)2 could be a good alternative for the T2D
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